Abcodia Ltd is a clinical stage company engaged in the commercial development of novel tests for the early detection of cancer. The Company’s first product is the ROCA© Test for the early detection of ovarian cancer, and it is expanding its pipeline of early detection technologies for lung, colorectal and pancreatic cancer. Abcodia’s offerings are based on expertise in measuring and modelling dynamic changes over time of clinical variables including test results from serum-based markers before cancer is clinically diagnosed. The company maintains exclusive commercial access to a biobank of five million serum samples donated from more than 200,000 individuals over a 10-year period and holds strategic collaborations with leading global organizations including Cancer Research UK, University College London and other academic and industry partners.
Abcodia is a privately held company funded through investments from Albion Ventures, Cambridge Innovation Capital, Scottish Equity Partners and UCL Business. Headquartered in Cambridge, U.K., the Company has operations in Boston, Mass. and a clinical laboratory in Memphis, Tenn.

Company Growth (employees)
Type
Private
HQ
Cambourne, GB
Founded
2010
Size (employees)
25 (est)
Abcodia was founded in 2010 and is headquartered in Cambourne, GB

Key People/Management at Abcodia

Nadia Altomare

Nadia Altomare

CEO
Chris Poole

Chris Poole

CFO
Julie Barnes

Julie Barnes

Founding CEO and Chief Scientific Officer

Abcodia Office Locations

Abcodia has offices in Cambourne, Boston and Memphis
Cambourne, GB (HQ)
1010 Cambourne Business Park
Cambourne, GB
Cambourne Rd
Memphis, US
201 3495 Hacks Cross Rd
Boston, US
745 Atlantic Ave

Abcodia Financials and Metrics

Summary Metrics

Founding Date

2010

Total Funding

$17 m

Latest funding size

$8.3 m

Time since last funding

over 2 years

Investors

Abcodia's latest funding round in May 2015 was reported to be $8.3 m. In total, Abcodia has raised $17 m

Abcodia Financials

Abcodia's revenue was reported to be £568.3 k in FY, 2015
GBP

Revenue (FY, 2015)

568.3 k

Gross profit (FY, 2015)

539.7 k

Gross profit margin (FY, 2015), %

95%

Net income (FY, 2015)

(2.7 m)

EBITDA (FY, 2015)

(2.7 m)

EBIT (FY, 2015)

(2.7 m)

Cash (31-Dec-2016)

714.4 k
GBPFY, 2015

Revenue

568.3 k

Cost of goods sold

28.5 k

Gross profit

539.7 k

Gross profit Margin, %

95%
GBPFY, 2015

Net Income

(2.7 m)

Income Taxes Paid

82.1 k
    Y, 2016

    Financial Leverage

    -1.3 x
    Show all financial metrics

    Abcodia's Web-traffic and Trends

    Abcodia Online and Social Media Presence

    Abcodia Company Life and Culture

    You may also be interested in